Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic updates AneuRx system

This article was originally published in The Gray Sheet

Executive Summary

A newer version of Medtronic's AneuRx AAAdvantage abdominal aortic aneurysm (AAA) stent graft with the Xcelerant delivery system wins FDA approval. Updates to the new system include improved radiopaque markers and stent contouring. Roughly 1.2 mil. people in the United States have AAA, though only 15% are ever diagnosed, according to Medtronic. The AneuRx system was originally launched in the U.S. in 1996 (1"The Gray Sheet" Nov. 28, 2005, p. 9)...

You may also be interested in...



Endovascular AAA Repair Requires Reintervention More Often Than Surgery

Reintervention to address abdominal aortic aneurysm (AAA) repair complications is more common following endovascular procedures than with open surgery, according to Vascular Surgery Chief Jan Blankensteijn, MD, Radboud University Nijmegen Medical Center, The Netherlands

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel